Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis-Reference-Cited by-同舟云学术

Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis

Published:2020-05 Issue:5 Volume:6 Page:400-402
ISSN:2352-5126
Container-title:JAAD Case Reports
language:en
Short-container-title:JAAD Case Reports

Author:

Qiu Connie,Shevchenko Alina,Hsu Sylvia

Publisher

Elsevier BV

Subject

Dermatology

Reference16 articles.

1. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial;Robert;Lancet,2014

2. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells;Alissafi;J Autoimmun,2019

3. Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events;Chan;J Am Acad Dermatol,2019

4. Pembrolizumab-induced bullous pemphigoid;Sun;JAAD Case Rep,2019

5. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors;Lopez;Int J Dermatol,2018

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitor‐induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications;The Journal of Dermatology;2023-11-30

2. Bullous Pemphigoid in a Centenarian Male Simulating Toxic Epidermal Necrolysis;Cureus;2023-09-11

3. Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid;Frontiers in Oncology;2023-03-03

4. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer;JAMA Dermatology;2022-08-01

5. Skin Manifestation Induced by Immune Checkpoint Inhibitors;Clinical, Cosmetic and Investigational Dermatology;2022-05